Drug screening for Pelizaeus-Merzbacher disease by quantifying the total levels and membrane localization of PLP1.

Kouga, Takeshi; Koizume, Shiro; Aoki, Shiho; Jimbo, Eriko; Yamagata, Takanori; Inoue, Ken; Osaka, Hitoshi

Kouga, Takeshi; Koizume, Shiro; Aoki, Shiho; Jimbo, Eriko; Yamagata, Takanori; Inoue, Ken; Osaka, Hitoshi.

Afiliación

Kouga T; Department of Pediatrics, Jichi Medical University, Tochigi, Japan.
Koizume S; Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Aoki S; Department of Pediatrics, Jichi Medical University, Tochigi, Japan.
Jimbo E; Department of Pediatrics, Jichi Medical University, Tochigi, Japan.
Yamagata T; Department of Pediatrics, Jichi Medical University, Tochigi, Japan.
Inoue K; Department of Mental Retardation and Birth Defect Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Japan.
Osaka H; Department of Pediatrics, Jichi Medical University, Tochigi, Japan.

Mol Genet Metab Rep ; 20: 100474, 2019 Sep.

Article en En | MEDLINE | ID: mdl-31110947

Palabras clave

CNS, Central nervous systems; Drug screening; EGFP, Enhanced green fluorescent protein; ER, Endoplasmic reticulum; ER-associated degradation; Gene expression; IPA, Ingenuity pathways analysis; IRE1 α, Inositol requiring enzyme 1 α; Membrane protein; Oligodendrocyte; PLP1; PLP1, Proteolipid protein 1; PMD, Pelizaeus-Merzbacher disease; UPR, Unfolded protein response; XBP1, X-box binding protein 1; msd, Myelin synthesis deficient

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Screening_studies Idioma: En Revista: Mol Genet Metab Rep Año: 2019 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google